Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
-
If you are wondering whether CG Oncology's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for this stock.
-
Over the past week the share price return was 3.9%, over the last month it was 20.1%, year to date it was 53.8%, and over the past year it was 131.3%, which naturally raises questions about what is already baked into the current US$64.29 price.
-
Recent news coverage has focused on CG Oncology as a cancer focused biotech name, which helps explain why investors are paying close attention to its progress and prospects. This context is important when thinking about whether the current market enthusiasm aligns with a sensible assessment of what the business might be worth.
-
On our valuation checks CG Oncology scores 3 out of 6 for potential undervaluation, giving it a value score of 3 , and next we will look at what different valuation approaches imply about the stock, before finishing with a way to think about value that goes beyond any single model.
Approach 1: CG Oncology Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes projections of a company's future cash flows and discounts them back to today using a required rate of return. This gives an estimate of what the whole business might be worth now.
For CG Oncology, the model used is a 2 Stage Free Cash Flow to Equity approach. The company currently reports last twelve month free cash flow of a loss of $132.63 million. Analyst projections supplied to the model run out to 2030, with free cash flow estimates moving from a loss of $225.39 million in 2026 and $200.09 million in 2027, to positive $20.81 million in 2028, $340.37 million in 2029 and $590.04 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates additional years of free cash flow to complete the DCF.
On this basis, the DCF model arrives at an estimated intrinsic value of $303.83 per share, compared with the current share price of $64.29. That gap implies the stock is 78.8% undervalued according to this specific cash flow based approach.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests CG Oncology is undervalued by 78.8%. Track this in your watchlist or portfolio , or discover 48 more high quality undervalued stocks .
Approach 2: CG Oncology Price vs Book
For companies that are not yet profitable, earnings based metrics like P/E are less useful, so investors often look at asset based measures such as the Price to Book, or P/B, ratio instead. Book value gives you a simple snapshot of what the market is paying relative to the company's net assets.
What counts as a normal P/B ratio depends on what investors expect for growth and how they view the risks. Higher expected growth or lower perceived risk can justify a higher P/B, while slower growth or higher risk tends to line up with a lower, more conservative multiple.
CG Oncology currently trades on a P/B of 7.21x. That compares with an average P/B of 2.57x for the Biotechs industry and a peer group average of 9.99x. The stock therefore sits above the sector but below peers. Simply Wall St's Fair Ratio metric estimates what a more tailored P/B could look like after factoring in elements such as growth outlook, risks, profit margins, market cap and the company's specific industry. This can be more informative than using broad industry or peer averages alone. As the Fair Ratio is not available here, this approach does not provide a clear under or overvaluation signal.
Result: ABOUT RIGHT
P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies .
Upgrade Your Decision Making: Choose your CG Oncology Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company tied directly to the numbers you think are reasonable for its future revenue, earnings, margins and fair value.
With a Narrative, you connect what you believe about CG Oncology's business to a clear financial forecast, and then to an estimated fair value per share that you can compare with today's US$64.29 price.
Narratives are available on Simply Wall St's Community page. Millions of investors use them as an easy and accessible tool to see whether their own fair value suggests they might want to buy, hold, or sell. Each Narrative automatically refreshes when new information such as news or earnings is added to the platform.
For CG Oncology, one investor might build a Narrative that supports a much higher fair value, while another uses more cautious assumptions and lands on a far lower figure. This shows how the same stock can look very different depending on your own expectations and risk tolerance.
Do you think there's more to the story for CG Oncology? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CGON .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
